Integrating Artificial Intelligence into Annual Product Quality Review: A New Era in Pharmaceutical Quality Assurance

The Annual Product Quality Review (APQR) is a required, structured, and documented evaluation of pharmaceutical products that occurs over a one-year period. Pharmaceutical manufacturers conduct a systematic Annual Product Quality Review (APQR) of product quality data each year. The primary goal is to assess the quality, safety, and effectiveness of medicinal products at all stages of their development. The system covers production, analytical findings, discrepancies, grievances, refunds, data on stability, and CAPA initiatives to guarantee continuous conformity with Current Good Manufacturing Practices (cGMP) and worldwide regulatory guidelines. APQR facilitates consistency across products, identifies potential risks, validates processes, and manages quality throughout the product lifecycle. The review conforms to regulatory guidelines like FDA 21 CFR 211.180(e), EU GMP Annex 15, ICH Q7/Q9/Q10, and PIC/S standards, encouraging ongoing improvement and inspection preparedness. This is based on regulatory requirements and standards that govern the manufacture and maintenance of pharmaceutical product quality. The pharmaceutical industry is adopting digital transformation to guarantee improved product quality and regulatory adherence by incorporating Artificial Intelligence (AI) into all quality assessments and characteristics. The integration of artificial intelligence in APQR improves both its efficiency and accuracy. Predictive analytics and anomaly detection will be achieved by utilizing AI and machine learning technologies in the future. This article offers a comprehensive framework for APQR, covering regulatory context, scope, documentation, and implementation strategies within pharmaceutical quality systems.